Keywords: BioAlliance Pharma, Validive, Clonidine Lauriad, Ph II, USA, Oral mucositis, Head and neck cancer patients

BioAlliance Pharma extends Ph II Validive trial to USA

Article | 19 February 2013

Print This

French biotech firm BioAlliance Pharma (Euronext Paris – BIO) has announced the extension of its Phase II clinical trial with ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in